UCB completes acquisition of Candid Therapeutics, strengthening next generation immunology pipeline
Brussels (Belgium), 17 June, 2026, 07:00 (CEST) – UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the successful completion of its previously announced acquisition of Candid Therapeutics (Candid), a clinical-stage biotechnology company developing novel T-cell engager (TCE) therapies for autoimmune and inflammatory diseases. The acquisition strengthens UCB’s position as an innovator in immunology and […]